SCHEMBL2969158

SCHEMBL2969158

COc1cc(CCC(O)c2ccc(O)cc2O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.58
PTPN1 P18031 1/20 0.55
HTR1A P08908 1/20 0.54
TAAR1 Q96RJ0 2/20 0.54
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
LMNA P02545 1/20 0.52
GLA P06280 1/20 0.52
MAOB P27338 1/20 0.50
TMEM97 Q5BJF2 1/20 0.50
SIGMAR1 Q99720 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29684225 1.00 ADRB2 (0.58) ADRB2PTPN1HTR1ATAAR1TSHR
SCHEMBL29684134 0.92 STAT3 (0.57) ADRB2TSHRLMNA
SCHEMBL2970029 0.92 STAT3 (0.57) ADRB2TSHRLMNA
SCHEMBL2978394 0.83 CALM1 (0.51) ADRB2
SCHEMBL28050423 0.83 PTPN1 (0.51) ADRB2PTPN1HTR1ATAAR1TSHR
SCHEMBL29684623 0.83 ALOX15 (0.50) ADRB2HTR1ATAAR1TSHRMAPK1
SCHEMBL2977752 0.83 ALOX15 (0.50) ADRB2HTR1ATAAR1TSHRMAPK1
SCHEMBL2975079 0.81 TTR (0.50) ADRB2TAAR1
SCHEMBL1853092 0.81 AKR1B1 (0.48) PTPN1
SCHEMBL30576431 0.81 AKR1B1 (0.48) PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210085580-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN, INC. (US) 2021-03-25 US claimed
US-20200170907-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN, INC. (US) 2020-06-04 US claimed
US-20160193126-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN INC (US) 2016-07-07 US claimed
EP-1748767-A4 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN PHARMACEUTICALS INC (US) 2008-12-24 EP claimed
US-20080132581-A1 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae UNIGEN PHARMACEUTICALS, INC. (US) 2008-06-05 US claimed
EP-1748767-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES Unigen Pharmaceuticals, Inc. (US) 2007-02-07 EP claimed
WO-2005117849-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN PHARMACEUTICALS, INC. (US) 2005-12-15 WO claimed
US-20050267047-A1 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN PHARMACEUTICALS, INC. (US) 2005-12-01 US claimed
US-11857657-B2 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN, INC. (US) 2024-01-02 US disclosed
US-11857657-B2 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN, INC. (US) 2024-01-02 US disclosed
US-11857657-B2 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN, INC. (US) 2024-01-02 US disclosed
US-20210085580-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN, INC. (US) 2021-03-25 US disclosed
US-20210085580-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN, INC. (US) 2021-03-25 US disclosed
US-10857082-B2 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN, INC. (US) 2020-12-08 US disclosed
US-20080132581-A1 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae UNIGEN PHARMACEUTICALS, INC. (US) 2008-06-05 US disclosed
US-20080132581-A1 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae UNIGEN PHARMACEUTICALS, INC. (US) 2008-06-05 US disclosed
US-20080132581-A1 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae UNIGEN PHARMACEUTICALS, INC. (US) 2008-06-05 US disclosed
EP-1748767-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES Unigen Pharmaceuticals, Inc. (US) 2007-02-07 EP disclosed
WO-2005117849-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN PHARMACEUTICALS, INC. (US) 2005-12-15 WO disclosed
US-20050267047-A1 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN PHARMACEUTICALS, INC. (US) 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200170907-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES TYR, DDT, HAAO ADRB2 2316/4885PTPN1 1357/4885HTR1A 2899/4885
US-20050267047-A1 Diarylalkanes as potent inhibitors of binuclear enzymes TYR, DDT, HAAO ADRB2 2316/4885PTPN1 1357/4885HTR1A 2899/4885
US-20160193126-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES TYR, DDT, HAAO ADRB2 2316/4885PTPN1 1357/4885HTR1A 2899/4885
US-10857082-B2 Diarylalkanes as potent inhibitors of binuclear enzymes TYR, DDT, HAAO ADRB2 2316/4885PTPN1 1357/4885HTR1A 2899/4885
US-20210085580-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES TYR, DDT, HAAO ADRB2 2316/4885PTPN1 1357/4885HTR1A 2899/4885
US-20080132581-A1 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae TYR, MAOA, CYP51A1 ADRB2 3586/4885PTPN1 3131/4885HTR1A 1154/4885
US-11857657-B2 Diarylalkanes as potent inhibitors of binuclear enzymes TYR, DDT, HAAO ADRB2 2316/4885PTPN1 1357/4885HTR1A 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.